HBV受体研究新进展  

Recent advances in the study of HBV receptor

作　　者：林少唯 李冬[1] 唐丽华[2] 李宝华[1] 徐希柱[1] 陈强[1] 田兆菊[1] 田景惠[1] LIN Shao-wei;LI Dong;TANG Li-hua;LI Bao-hua;XU Xi-zhu;CHEN Qiang;TIAN Zhao-ju;TIAN Jing-hui(School of Public Health,Taishan Medical University,Taian,Shandong,China 271000;Blood Transfusions,Taian City Central Hospital)

机构地区：[1]泰山医学院公共卫生学院,山东泰安271000 [2]泰安市中心医院输血科

出　　处：《中国病原生物学杂志》2018年第11期1296-1299,共4页Journal of Pathogen Biology

基　　金：国家自然科学基金项目(No.31500148);泰安市科技发展计划资助项目(No.2015NS1131,201440774-13)

摘　　要：HBV流行久远、传播广泛。HBV感染所致的乙型肝炎一直是全球性公共卫生问题。HBV通过与靶细胞表面的受体结合从而启动感染。HBV被发现后的四十余年中,人们一直致力于寻找其受体,虽有诸多报导但均未被认可,直到Na^+-牛磺胆酸共转运蛋白(NTCP)被鉴定为HBV的功能性受体并得到了公认。这一发现使得人们对HBV的感染机制有了进一步认识,并为HBV的基础研究与临床治疗提供了新的方向。Hepatitis B virus (HBV)has long been prevalent and widespread.Hepatitis B caused by HBV infection has always been a global public health problem.HBV initiates infection by binding to a receptor on the surface of the target cell.Researchers have been dedicated to finding the receptor of HBV for more than 40 years since HBV was discovered. Many studies have been reported,but none have been accepted until sodium taurocholate cotransporting polypeptide (NTCP)was identified and recognized as a functional receptor for HBV.This discovery has led to further understanding of the mechanism of infection of HBV and it provides a new direction for basic research and clinical treatment of HBV.

关 键 词：乙型肝炎病毒 受体 Na^+-牛磺胆酸共转运蛋白 综述 

分 类 号：R373.21[医药卫生—病原生物学]